Harbin Jixianglong Biotech Co., Ltd. has issued a voluntary recall for several lots of Semaglutide intended for prescription compounding. The recall was initiated because the manufacturer failed to complete necessary process validation and bacterial endotoxin testing before distributing the product. These products are sold in various sizes ranging from 1 gram to 100 grams for use by compounding pharmacies.
The lack of proper bacterial endotoxin validation means the product may contain harmful impurities that could cause severe inflammatory responses or infections when the drug is compounded and administered to patients.
Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China | Recall #: D-0379-2026
Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China | Recall #: D-0380-2026
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.